It has been a mixed earnings season for the drug and biotech sector so far. While several large drug/biotech companies beat estimates for both earnings and revenues, others like Pfizer missed on both ...

Angion Biomedica (ANGN) stock has had a difficult run since the company's shares leapt in initial trading after its IPO on Feb. 9, which raised $92m via the issuance of 5.75m shares at a price of $16.

Today, we take our first in-depth look at a small biotech developmental firm that went public just less than a year ago, but is already deep in 'Busted IPO' territory. It popped up on our radars ...

Angion Biomedica Corp. ANGN announced that it has entered into a definitive merger agreement with the privately-held biotech, Elicio Therapeutics, wherein the latter will merge with a wholly-owned ...